Casgevy is the first medicine to be licensed that uses the gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020, Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) said.
https://www.pharmalive.com/wp-content/uploads/2020/09/Vertex-Logo-R_colorRGB.jpg252480Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-11-16 05:58:412023-11-16 08:56:12UK authorizes gene therapy for blood disorders in world first
